Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Saudi Arabia · Delayed Price · Currency is SAR

114.20

-0.60 (-0.52%)

Nov 5, 2026, 3:17 PM AST

Market Cap	7.99B -25.7%
Revenue (ttm)	1.59B +8.9%
Net Income	484.13M +8.2%
EPS	6.92 +8.2%
Shares Out	70.00M
PE Ratio	16.51
Forward PE	15.13
Dividend	4.40 (3.85%)
Ex-Dividend Date	Aug 2, 2026

Volume	48,095
Open	115.00
Previous Close	114.80
Day's Range	114.10 - 116.90
52-Week Range	112.20 - 163.70
Beta	0.38
Analysts	Hold
Price Target	152.16 (+33.24%)
Est. Earnings	Feb 23, 2027

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceutica... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1994

Employees 1,255

Stock Exchange Saudi Stock Exchange

Ticker Symbol 4015

Full Company Profile

Financial Performance

In 2025, TADAWUL:4015's revenue was 1.50 billion, an increase of 13.82% compared to the previous year's 1.32 billion. Earnings were 463.80 million, an increase of 30.09%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 4015 stock is "Hold." The 12-month stock price target is SAR 152.16, which is an increase of 33.24% from the latest price.

Price Target

SAR 152.16

(33.24% upside)

Analyst Consensus: Hold

Stock Forecasts